AstraZeneca and Revna Biosciences Partner to Strengthen Lung Cancer Care
Thursday, July 31, 2025
AstraZeneca and Revna Biosciences have expanded their collaboration to improve lung cancer care in Ghana, following a strategic partnership first announced in April 2025.
The initiative is making steady progress in addressing key challenges in diagnosis, treatment, and access to targeted therapies for patients across the country.
As part of this effort, AstraZeneca has introduced a targeted therapy for patients with EGFR-mutated lung cancer in Ghana. This marks a significant milestone in the partnership’s aim to bring modern treatment options to underserved regions in sub-Saharan Africa.
The collaboration focuses on improving several critical areas of cancer care:
Diagnostic and Clinical Training: A lung cancer symposium and training programme were conducted to support local healthcare professionals in adopting advanced diagnostic tools and protocols.
Biomarker Integration: EGFR biomarker testing has been incorporated into workflows at leading cancer centres to support precision oncology and guide treatment decisions.
Patient Access to Care: A scalable system has been developed to connect molecular testing with personalised treatment options, helping patients begin therapy without unnecessary delays.
Data-Driven Infrastructure: A platform has been set up to support real-time data collection and analysis. This is intended to improve clinical decision-making and support future research in areas such as treatment response and resistance.
The partnership reflects a shared commitment to building long-term solutions for cancer care by combining advanced diagnostics with access to innovative therapies. In doing so, AstraZeneca and Revna Biosciences are working to close long-standing gaps in cancer treatment in Ghana.
By embedding precision medicine into the healthcare framework, the initiative is setting a new standard for cancer care in the region.
The collaboration is also supporting the development of genomic and real-world evidence to inform future strategies in cancer diagnostics and treatment.
Source: businesswire.com
